The AEGEAN Phase 3 Trial of Neoadjuvant/Adjuvant Durvalumab in Patients with Resectable Stage II/III NSCLC

被引：20
|
作者：
Heymach, J. [1 ]
Taube, J. [2 ]
Mitsudomi, T. [3 ]
Harpole, D. [4 ]
Aperghis, M. [5 ]
Trani, L. [5 ]
Powell, M. [6 ]
Dennis, P. [6 ]
Reck, M. [7 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Johns Hopkins Univ, Baltimore, MD USA
[3] Kindai Univ, Fac Med, Dept Surg, Div Thorac Surg, Osakasayama, Japan
[4] Duke Univ, Dept Surg, Durham, NC USA
[5] Astrazeneca, Cambridge, England
[6] Astrazeneca, Gaithersburg, MD USA
[7] Airway Res Ctr North, Grosshansdorf, Germany
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Chemotherapy; durvalumab; NSCLC;
D O I：
10.1016/j.jtho.2019.08.1318
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.18-02
引用
收藏
页码：S625 / S626
页数：2
相关论文
共 50 条
  • [31] Checkmate 77T: A phase III trial of neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant nivo in resectable early-stage NSCLC.
    Cascone, Tina
    Provencio, Mariano
    Sepesi, Boris
    Lu, Shun
    Aanur, Nivedita
    Li, Sunney
    Spicer, Jonathan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] NeoPeLe: A phase II trial of neoadjuvant (NAT) pembrolizumab (Pembro) combined with lenvatinib (Lenva) in resectable stage III melanoma
    Long, G. V.
    Spillane, A. J.
    Pennington, T. E.
    Shannon, K. F.
    Stretch, J.
    Gonzalez, M.
    Saw, R. P. M.
    Lo, S. N.
    Scolyer, R. A.
    Menzies, A. M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S906 - S907
  • [33] PACIFIC-6: A Phase II Study of Durvalumab Following Sequential Chemoradiotherapy in Patients with Stage III, Unresectable NSCLC
    Garassino, M.
    Faivre-Finn, C.
    Mazieres, J.
    Reck, M.
    Emeribe, U.
    Franks, A.
    Trunova, N.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S403 - S404
  • [34] PACIFIC-6: A Phase II Study of Durvalumab after sequential Chemoradiotherapy in Patients with unresectable Stage III NSCLC
    Wuerschmidt, F.
    Garassino, M.
    Faivre-Finn, C.
    Mazieres, J.
    Emeribe, U.
    Franks, A.
    Trunova, N.
    Reck, M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (SUPPL 1) : S88 - S88
  • [35] An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy
    Verma, Saurav
    Breadner, Daniel
    Mittal, Abhenil
    Palma, David A.
    Nayak, Rahul
    Raphael, Jacques
    Vincent, Mark
    CANCERS, 2024, 16 (07)
  • [36] A randomized phase II neoadjuvant trial in patients with stage II-III and inflammatory breast cancer
    Somlo, G.
    Paz, B.
    Shen, J.
    Garberoglio, C.
    Luu, T.
    Chung, C.
    Hurria, A.
    Frankel, P.
    Baker, N.
    Wilczynski, S.
    Arnold, K.
    Yeb, Y.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S231 - S231
  • [37] Phase 3 trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8).
    Ozguroglu, Mustafa
    Levy, Benjamin Philip
    Horinouchi, Hidehito
    Yu, Jinming
    Grainger, Ellie
    Phuong, Patrick Hoang
    Peterson, Daniel
    Newton, Michael David
    Spira, Alexander I.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [38] AFT-16: Phase II trial of neoadjuvant and adjuvant atezolizumab and chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC).
    Ross, Helen J.
    Kozono, David E.
    Urbanic, James John
    Williams, Terence Marques
    DuFrane, Carter
    Bara, Ilze
    Schulze, Katja
    Brockman, Jane Michelle
    Wang, Xiaofei F.
    Gao, Junheng
    Vokes, Everett E.
    Stinchcombe, Tom
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] A phase II study of atezolizumab as neoadjuvant and adjuvant therapy in patients (pts) with resectable non-small cell lung cancer (NSCLC).
    Owen, Dwight Hall
    Bunn, Paul A.
    Johnson, Bruce E.
    Kwiatkowski, David J.
    Kris, Mark G.
    Wistuba, Ignacio Ivan
    Gandhi, Mayank
    Phan, See
    Shames, David S.
    Schulze, Katja
    Yu, Wei
    Aisner, Dara
    Chaft, Jamie E.
    Garon, Edward B.
    Lee, Jay M.
    Minna, John D.
    Rusch, Valerie W.
    Reckamp, Karen L.
    Wozniak, Antoinette J.
    Carbone, David P.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [40] The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma.
    Lucas, Minke W.
    Lijnsvelt, Judith
    Pulleman, Saskia
    Scolyer, Richard A.
    Menzies, Alexander M.
    Van Akkooi, Alexander Christopher Jonathan
    Van Houdt, Winan J.
    Shannon, Kerwin Frank
    Pennington, Thomas
    Suijkerbuijk, Karijn
    Kapiteijn, Ellen
    Van der Veldt, Astrid Aplonia Maria
    Carlino, Matteo S.
    Sandhu, Shahneen
    Gonzalez, Maria
    Klop, Charlotte L. Zuur W. Martin. C.
    Long, Georgina V.
    Blank, Christian U.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345